Yale University

1. Pfizer Inc. $15,101,695 861 payments
2. Eli Lilly and Company $11,311,857 187 payments
3. Merck Sharp & Dohme Corporation $10,800,418 294 payments
4. Janssen Research & Development, LLC $8,285,753 735 payments
5. Eisai Inc. $8,075,211 799 payments
6. AbbVie, Inc. $7,914,210 1,754 payments
7. AstraZeneca Pharmaceuticals LP $7,910,710 212 payments
8. Genentech, Inc. $7,214,902 890 payments
9. Gilead Sciences, Inc. $6,924,597 419 payments
10. E.R. Squibb & Sons, L.L.C. $5,929,332 153 payments

1. An Interventional Decentralized Efficacy and Safety Phase 2 Doubleblind 2Arm Study to Investigate Orally Administered Nirmatrelvirritonavir Compared With Placeboritonavir in Participants With Long Covid $3,995,418 8 payments
2. Study name not reported $3,447,593 77 payments
3. Tagrisso Collaborations Yale Univ $3,084,578 7 payments
4. A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $3,009,470 42 payments
5. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $2,543,507 2 payments
6. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $2,362,941 64 payments
7. A phase II evaluation of pembrolizumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent hypermutated,ultramutated endometrial cancer identified by next generation sequencing NGS and comprehensive genomic profiling CGP $2,208,720 10 payments
8. Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease -A4 Study $1,974,420 8 payments
9. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $1,944,843 52 payments
10. Study name not reported $1,937,041 2 payments

1. Other $1,812,658 79 payments
2. Patient care $688,841 45 payments
3. Medical research writing or publication $313,416 6 payments
4. Professional salary support $127,073 12 payments
5. Overhead $105,490 20 payments
6. Non-patient care $39,166 17 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.